To the yahoo finance and Stocktwits flunkies. See if you can stay focused.
Why a Strategic Sale in Q4 2026 Is the Highest-Probability Outcome
Fellow shareholders,
After reviewing the latest filings, earnings transcripts, trial timelines, and Sarissa’s track record, the data points strongly to a Q4 2026 (Oct–Dec) announcement window for a value-maximizing strategic transaction. This is not speculation — it is the logical convergence of operational, clinical, legal, and incentive factors.
Here are the ranked pillars of the thesis, ordered by strength and impact:
1. Recordati Partnership Ramp – Clean Q3 2026 Comparisons (Highest Confidence / Highest Impact)
Management explicitly stated in the April 29 earnings release: “Quarter-to-quarter European sales comparisons that reflect the partnership model with Recordati will commence in Q3 2026.” Q1 2026 European revenue was still transitional. The first true run-rate read arrives with Q3 earnings in late October. This is the single biggest operational de-risking event and gives Barclays verifiable data to market the royalty stream.
2. EMT2 Topline Data Window (High Confidence)
NCT03428477 primary completion was November 30, 2025; study completion April 30, 2026. Academic Phase 3 timelines place topline in late Q2 or Q3 2026. Positive data adds oncology-adjacent 505(b)(2) optionality and strengthens the “EPA tissue/platform” narrative.
3. SCOTUS Decision (High Confidence)
Oral argument was April 29, 2026; decision expected June/July. Removes the major legal overhang on the Hikma skinny-label case and improves IP defensibility for any buyer.
4. LREtEPA Patent Prosecution (Medium-High Confidence)
Application 18/472,875 filed September 2023. USPTO timelines place first Office Action in the May–August 2026 window (with possible Track One acceleration). This adds composition-of-matter protection and new 505(b)(2) optionality.
5. Sarissa Compensation & Change-in-Control Acceleration (High Confidence)
The April 10, 2026 DEF 14A and 2020 Stock Incentive Plan contain standard single/double-trigger acceleration for executives, directors, and Sarissa-affiliated members upon a change in control. This aligns everyone with a 2026 exit.
6. IRWD Realized Capital Loss Tax Offset (High Confidence)
Sarissa sold ~6.73 million IRWD shares in March 2026 at a realized loss. This loss can offset capital gains realized in the same 2026 tax year, improving net proceeds on an Amarin sale.
7. Barclays Engagement & Strategic Review (Confirmed but Foundational)
Engaged since June 2025. Provides the infrastructure for a competitive auction once the above catalysts align.
Bottom Line
By late October 2026 (post Q3 earnings), Barclays will have a clean, de-risked package: verified Recordati economics, SCOTUS resolution, LREtEPA progress, EMT2 visibility, and strong incentive alignment. This is the highest-probability window for a strategic announcement. Sarissa’s cost basis (~$70 post r/s), tax-loss offset, and compensation structure all favor closing in 2026 rather than deferring.
The current market cap (~$300M, near net cash) continues to assign near-zero probability to these catalysts. That is the asymmetry we have been discussing.
AI
Market Data 
Markets 
